Market: Euronext Paris
ISIN code Mnemo: CH0308403085 GNRO
Web site: www.geneuro.com
Regulatory News:
Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of December 31, 2018, the following assets appeared on the liquidity account:
Number of shares: | 66,507 | |
Cash balance of the liquidity account: | 164,789.34 |
As a reminder, as of June 30, 2018, the following resources were booked to the liquidity account:
Number of shares: | 51,934 | |
Cash balance of the liquidity account: | 255,399.30 |
About GeNeuro
GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis or Type 1 Diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 28 employees and rights to 16 patent families protecting its technology.
For more information, visit: www.geneuro.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005372/en/
Contacts:
GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
investors@geneuro.com
NewCap (France)
Mathilde Bohin (investors)
+33 1 44 71 98 52
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu
Halsin Partners
Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com
LifeSci Advisors
Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com